Solid Tumors
Conditions
Keywords
BA1106, First in human study, safety
Brief summary
This is an open label Phase 1, First in Human trial designed to evaluate the safety, tolerability pharmacokinetics, preliminary efficacy of BA1106 in participants with advanced solid tumors.
Detailed description
BA1106 is a human anti-CD25 monoclonal antibody. There are two parts in the study. Part A is dose escalation study, and Part B is dose expansion study. Part A will be conducted using BOIN dose escalation method at the dosing regimen of once every 3 weeks. In Part B, 1\ 2 dose levels, dosing regimens (i.e. once every 2 weeks or once every 3 weeks), and 1\ 4 selected indications will be chosen to further evaluate the safety and efficacy of BA1106.
Interventions
DRUGBA1106
In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W). In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W).
Sponsors
Shandong Boan Biotechnology Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Able and willing to provide written informed consent and to comply with the study protocol; 2. Subject with histologically or cytologically confirmed advanced and/or metastatic solid tumors who have progressed on all standard therapies, are intolerant to Standard-Of-Care (SOC), and/or are non-amenable to SOC; 3. At least one evaluable lesion in Part A and at least one measurable lesion in Part B according to RECIST v1.1; 4. Able to provide the most recent archival tumor tissue samples (negotiable); 5. Life expectancy \>=12 weeks; 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 7. Adequate major organ function; 8. Women of Childbearing Potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods; 9. Men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods and refrain from donating sperm.
Exclusion criteria
1. Participants with active central nervous system (CNS) metastases causing clinical symptoms or metastases that require therapeutic intervention; 2. Participants with any infection requiring intravenous therapy, or any other uncontrolled active infection, within 2 weeks prior to informed consent; 3. Participants with symptomatic radiation pneumonia, radiation esophagitis, radiation colitis; extensive interstitial lung disease of both lungs, chronic obstructive pulmonary disease requiring bronchodilators or regular hormonal therapy; unhealed peptic ulcers, cirrhosis and related complications, chronic enteritis, necrotizing enteritis, gastrointestinal obstruction (except those who are relieved with treatment and have no safety risk as assessed by the investigator), gastrointestinal bleeding tendency or high risk of perforation, pancreatitis requiring treatment; arteriovenous thrombotic disease; chronic nephritis and nephrotic syndrome, within 8 weeks prior to C1D1; 4. Participants with active autoimmune disease or the risk of recurrence; 5. Participants with major cardiocerebral vascular disease; 6. Participants with body cavity effusion requiring local treatment or determined as poorly controlled by the investigator; 7. History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or DIHS (drug-induced hypersensitivity syndrome); 8. Participants with diseases affecting intravenous injection and venous blood collection; 9. Prior use of any anti-cancer therapy (including chemotherapy, radiotherapy, targeted therapy, immunotherapy, traditional Chinese medicine, etc.) within 4 weeks, or non-antitumor traditional Chinese medicine within 2 weeks, prior to C1D1; 10. Prior use of drugs targeting IL-2 receptors; 11. History of being receipt of any organ transplantation or allogeneic stem-cell transplantation; 12. Risk of gastrointestinal ulcers or bleeding as assessed by the investigator; 13. Prior treatment with systemic immunosuppression excluding nasal/inhaled corticosteroids or physiological dosed systemic corticosteroids, within 2 weeks prior to C1D1; 14. Prior treatment with cytokine, blood transfusion, or blood products within 4 weeks prior to C1D1; 15. Participants with major surgical procedure or significant traumatic injury, within 4 weeks prior to C1D1; or with wound healing complications before enrolment; 16. Vaccination with live vaccines within 4 weeks prior to informed consent; 17. Known hypersensitivity to any of the components of BA1106; 18. Participants with grade 2 or higher toxicities from any previous therapies \[except for cases of alopecia and peripheral sensory neuropathy (both grade 2), which are allowed\]; 19. Positive for Hepatitis B and C, or positive HIV test at screening; 20. History of drug abuse, drug addiction, or alcoholism; 21. Pregnancy, lactation, or breastfeeding; 22. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (according to NCI CTCAE 5.0). | From the initiation of study treatment to the completion of safety follow-up after the end of study treatment, up to 2 years. |
Secondary
| Measure | Time frame |
|---|---|
| Half-life (t1/2) of BA1106 | up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days) |
| Maximum Concentration (Cmax) of BA1106 | up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days) |
| Minimum Concentration (Cmin) of BA1106 | up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days) |
| Time of maximum concentration (Tmax) of BA1106 | up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days) |
| Clearance (CL) of BA1106 | up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days) |
| Volume of distribution at steady-state conditions (Vss) of BA1106 | up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days) |
| Area under the curve (AUC) of BA1106 | up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days) |
| Incidence of Neutralizing Antibodies (Nab) during the study relative to the prevalence of Nab at baseline | up to 2 years |
| Objective Response Rate (ORR) | up to 2 years |
| Duration of Response (DOR) | up to 2 years |
| Disease Control Rate (DCR) | up to 2 years |
| Progression-Free Survival (PFS) | up to 2 years |
| Overall Survival (OS) | up to 2 years |
| Incidence and titer of Anti-Drug Antibodies (ADA) during the study relative to the prevalence of ADA at baseline | up to 2 years |
Countries
China
Contacts
Primary ContactLin Shen
Outcome results
None listed